search
Back to results

DBS for Depression

Primary Purpose

Treatment Resistant Depression

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Medtronic SenSight Directional DBS lead
Sponsored by
Northwell Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Treatment Resistant Depression focused on measuring TRD

Eligibility Criteria

22 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-V (SCID I/DSM-V) Age 22 - 70 years. 24-item Hamilton Depression Rating Scale (HDRS) score of at least 21 on the first 17 items and/or Montgomery-Asburg Depression Rating Scale (MADRS) score of at least 21. Global Assessment of Function (GAF) score of 45 or less A recurrent (equal or >4 episodes) or chronic (episode duration equal or higher >2 years) course AND a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior) over lifetime history as determined by an investigator As determined by the study psychiatrist/investigator, has treatment resistant depression defined as failure to respond to: 6.1. Adequate trials (equal or >6 weeks at an adequate dose) of primary antidepressants from at least 3 different classes AND; 6.2. adequate trials (equal>4 weeks at an adequate dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) AND; 6.3 An adequate trial of ECT (>6 bilateral treatments), or inability to tolerate an adequate ECT trial, AND; 6.4 An adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist). Able to comply with the operational and administrative requirements of participation in the study. Able to give written informed consent Patients with a history or diagnosis of generalized anxiety disorder (GAD) at the time of enrollment so long as Major Depressive Disorder (MDD) is the primary psychiatric diagnosis in the medical opinion of an investigator. On a stable psychiatric medication regimen beginning at least 6 weeks prior to enrollment and continuing through the first 6 months of the study, as determined by the investigator. Psychiatric medication changes can be made during the entirety of the subject's study participation but would be limited to the clinical judgment of the PI/study psychiatrist. At enrollment, provides the following information from at least two (2) verifiable contacts who reside within a 10-mile radius of the patient: name, relationship to patient, address (email mail); and telephone (mobile, home, work as applicable). Agrees to allow medical records requests and communications of any type to any and all health care providers who have seen the patient within five years of screening or enrollment. For the duration of study participation, agrees to be followed by a licensed psychiatrist and/or other licensed mental health practitioner on a regularly scheduled basis. Exclusion Criteria: Patients with any lifetime history of psychosis or psychotic disorder, according to DSM-V diagnostic criteria, or in the medical opinion of the PI/study psychiatrist. Any finding on the preoperative magnetic resonance imaging (MRI) scan that, in the opinion of the principal investigator and after consultation with the neuroradiologist, is, or might be, considered clinically significant such that participation in the study: (a) seems likely to increase the medical risk to the subject sufficient to outweigh the potential benefit to study participation; (b) seems likely to jeopardize the subject's ability to complete the study or fulfill all study requirements per protocol; or (c) may impact he integrity of the data or the validity of the results. Any previous surgery to destroy the treatment target (superolateral MFB) rendering it either unilaterally or bilaterally damaged such that it cannot be effectively stimulated, as visualized by pre-operative MRI scans, in the medical opinion of the PI Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/orinability to undergo presurgical MRI (cardiac pacemaker, implantable defibrillator or other implantable stimulator, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery. DBS contraindications include patients who are unable to properly operate the neurostimulator, and patients who will be exposed to MRI or diathermy. MRI and diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) are contraindicated because the energy can be transferred through the implanted System (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system. Transcranial Magnetic Stimulation (TMS) is contraindicated for patients with an implanted DBS System. Refusal of an adequate trial of ECT in the medical opinion of the study psychiatrist or PI following consultation with a study psychiatrist. History of stimulation intolerance in any area of the body. Within six (6) months of the enrollment date, has been diagnosed with, or has met the diagnostic criteria for, a substance abuse disorder (SUD) according to DSM-V criteria. Women of childbearing potential who, at enrollment or during the study: (a)have a positive urine pregnancy test; (b) are heterosexually active without the usage of a medically acceptable, highly effect contraceptive method* (≤1% pregnancy rate); or (c) are planning to become pregnant during the 60-month course of this study, as determined by the PI. *Examples include tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), and long-acting reversible contraceptives (LARC). Moderate-High Risk of Suicide according to the Columbia-Suicide Severity RatingScale (CSSRS) Screen Version-Recent (answers YES to Question 3 and NO to Question 6 (moderate risk) or YES to Question 4,5, or 6 (high risk)) and/or in the clinical judgment of the study psychiatrist or PI. Participation in another drug, device, or biologics trial within the preceding 30 days Presence of a condition requiring routine MRIs. Presence of a condition requiring diathermy. Subject is on anticoagulant medication. Prior to enrollment or during the course of the study and in the opinion of the PI, has a history of an medical, psychiatric, physical or non-physical disease, disorder, condition, injury, or disability; or has a non-medical reason (e.g., financial, logistical, personal, other) that: (a) may pose a significant risk to the patient; (b) may increase the possibility that the subject is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) may adversely impact the integrity of the data or the validity of the study results. Subjects without a fixed home address or stable living situation, in the opinion of the Principal Investigator.

Sites / Locations

  • Zucker Hillside HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Discontinuation Phase Group 1

Discontinuation Phase Group 2

Arm Description

Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.

Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.

Outcomes

Primary Outcome Measures

Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is the Montgomery-Asberg Depression Rating Scale, which at 12 months will be the primary endpoint. The investigators hypothesize is that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on MADRS scores. Also, that at 12 months 50% of the patients will be responders.

Secondary Outcome Measures

Global Assessment of Functioning (GAF) rated functional impairment
GAF measures how much a person's symptoms affect their daily life, on a scale of 1-100. The investigators hypothesize that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on GAF scores.
Clinical Global Impressions (CGI) rated severity
CGI is a clinician-determined summary based on all available information including severity, global improvement or change, and therapeutic response. The investigators hypothesize that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on CGI.
Measuring MADRS during discontinuation cross over weeks
Depression scores when the device is turned ON verses OFF, as assessed by the MADRS sale. The investigators hypothesize that MADRS values will differ significantly during the two-week period of discontinuation versus the 4-week period of ON.

Full Information

First Posted
September 18, 2023
Last Updated
October 19, 2023
Sponsor
Northwell Health
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT06096207
Brief Title
DBS for Depression
Official Title
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 18, 2023 (Actual)
Primary Completion Date
October 18, 2024 (Anticipated)
Study Completion Date
October 18, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Northwell Health
Collaborators
Medtronic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: Is deep brain stimulation effective in treating treatment resistant depression? Does deep brain stimulation improve overall clinical well-being and functioning? Participants will be implanted with a deep brain stimulation device. They will then be monitored over a 5-year period by using multiple questionnaires to track their depression symptoms. The device will be turned off at certain time points, unbeknown to the participant, to show the efficacy of the device when it is turned on. The device will be ON for 8.5 months and OFF for 3.5 months during the first year. Researchers will compare questionnaire scores when the device is off versus on to see if the device is working in reducing depression.
Detailed Description
This initial study at Northwell Health has the purpose to demonstrate the feasibility and safety of performing slMFB DBS as a treatment for TRD at Northwell Health as well as more clearly establish efficacy. The investigators hypothesize that DBS targeting can be consistently placed in the supero-lateral branch of the medial forebrain bundle (slMFB) after identification using diffusion tensor imaging and fiber tract analysis, as performed in DBS at UTHealth. The investigators will implant the Medtronic SenSight Directional DBS lead at this target location.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment Resistant Depression
Keywords
TRD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Discontinuation Phase Group 1
Arm Type
Experimental
Arm Description
Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
Arm Title
Discontinuation Phase Group 2
Arm Type
Experimental
Arm Description
Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
Intervention Type
Device
Intervention Name(s)
Medtronic SenSight Directional DBS lead
Intervention Description
At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
Primary Outcome Measure Information:
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
The MADRS is the Montgomery-Asberg Depression Rating Scale, which at 12 months will be the primary endpoint. The investigators hypothesize is that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on MADRS scores. Also, that at 12 months 50% of the patients will be responders.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Global Assessment of Functioning (GAF) rated functional impairment
Description
GAF measures how much a person's symptoms affect their daily life, on a scale of 1-100. The investigators hypothesize that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on GAF scores.
Time Frame
12 months
Title
Clinical Global Impressions (CGI) rated severity
Description
CGI is a clinician-determined summary based on all available information including severity, global improvement or change, and therapeutic response. The investigators hypothesize that there will be a significant effect of being stimulated (ON) versus not simulated (OFF) on CGI.
Time Frame
12 months
Title
Measuring MADRS during discontinuation cross over weeks
Description
Depression scores when the device is turned ON verses OFF, as assessed by the MADRS sale. The investigators hypothesize that MADRS values will differ significantly during the two-week period of discontinuation versus the 4-week period of ON.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-V (SCID I/DSM-V) Age 22 - 70 years. 24-item Hamilton Depression Rating Scale (HDRS) score of at least 21 on the first 17 items and/or Montgomery-Asburg Depression Rating Scale (MADRS) score of at least 21. Global Assessment of Function (GAF) score of 45 or less A recurrent (equal or >4 episodes) or chronic (episode duration equal or higher >2 years) course AND a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior) over lifetime history as determined by an investigator As determined by the study psychiatrist/investigator, has treatment resistant depression defined as failure to respond to: 6.1. Adequate trials (equal or >6 weeks at an adequate dose) of primary antidepressants from at least 3 different classes AND; 6.2. adequate trials (equal>4 weeks at an adequate dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) AND; 6.3 An adequate trial of ECT (>6 bilateral treatments), or inability to tolerate an adequate ECT trial, AND; 6.4 An adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist). Able to comply with the operational and administrative requirements of participation in the study. Able to give written informed consent Patients with a history or diagnosis of generalized anxiety disorder (GAD) at the time of enrollment so long as Major Depressive Disorder (MDD) is the primary psychiatric diagnosis in the medical opinion of an investigator. On a stable psychiatric medication regimen beginning at least 6 weeks prior to enrollment and continuing through the first 6 months of the study, as determined by the investigator. Psychiatric medication changes can be made during the entirety of the subject's study participation but would be limited to the clinical judgment of the PI/study psychiatrist. At enrollment, provides the following information from at least two (2) verifiable contacts who reside within a 10-mile radius of the patient: name, relationship to patient, address (email mail); and telephone (mobile, home, work as applicable). Agrees to allow medical records requests and communications of any type to any and all health care providers who have seen the patient within five years of screening or enrollment. For the duration of study participation, agrees to be followed by a licensed psychiatrist and/or other licensed mental health practitioner on a regularly scheduled basis. Exclusion Criteria: Patients with any lifetime history of psychosis or psychotic disorder, according to DSM-V diagnostic criteria, or in the medical opinion of the PI/study psychiatrist. Any finding on the preoperative magnetic resonance imaging (MRI) scan that, in the opinion of the principal investigator and after consultation with the neuroradiologist, is, or might be, considered clinically significant such that participation in the study: (a) seems likely to increase the medical risk to the subject sufficient to outweigh the potential benefit to study participation; (b) seems likely to jeopardize the subject's ability to complete the study or fulfill all study requirements per protocol; or (c) may impact he integrity of the data or the validity of the results. Any previous surgery to destroy the treatment target (superolateral MFB) rendering it either unilaterally or bilaterally damaged such that it cannot be effectively stimulated, as visualized by pre-operative MRI scans, in the medical opinion of the PI Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/orinability to undergo presurgical MRI (cardiac pacemaker, implantable defibrillator or other implantable stimulator, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery. DBS contraindications include patients who are unable to properly operate the neurostimulator, and patients who will be exposed to MRI or diathermy. MRI and diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) are contraindicated because the energy can be transferred through the implanted System (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system. Transcranial Magnetic Stimulation (TMS) is contraindicated for patients with an implanted DBS System. Refusal of an adequate trial of ECT in the medical opinion of the study psychiatrist or PI following consultation with a study psychiatrist. History of stimulation intolerance in any area of the body. Within six (6) months of the enrollment date, has been diagnosed with, or has met the diagnostic criteria for, a substance abuse disorder (SUD) according to DSM-V criteria. Women of childbearing potential who, at enrollment or during the study: (a)have a positive urine pregnancy test; (b) are heterosexually active without the usage of a medically acceptable, highly effect contraceptive method* (≤1% pregnancy rate); or (c) are planning to become pregnant during the 60-month course of this study, as determined by the PI. *Examples include tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), and long-acting reversible contraceptives (LARC). Moderate-High Risk of Suicide according to the Columbia-Suicide Severity RatingScale (CSSRS) Screen Version-Recent (answers YES to Question 3 and NO to Question 6 (moderate risk) or YES to Question 4,5, or 6 (high risk)) and/or in the clinical judgment of the study psychiatrist or PI. Participation in another drug, device, or biologics trial within the preceding 30 days Presence of a condition requiring routine MRIs. Presence of a condition requiring diathermy. Subject is on anticoagulant medication. Prior to enrollment or during the course of the study and in the opinion of the PI, has a history of an medical, psychiatric, physical or non-physical disease, disorder, condition, injury, or disability; or has a non-medical reason (e.g., financial, logistical, personal, other) that: (a) may pose a significant risk to the patient; (b) may increase the possibility that the subject is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) may adversely impact the integrity of the data or the validity of the study results. Subjects without a fixed home address or stable living situation, in the opinion of the Principal Investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Albert J Fenoy, MD
Phone
5165502100
Email
afenoy@northwell.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Miklos Argyelan, MD
Phone
7184708175
Email
margyelan@northwell.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Albert J Fenoy, MD
Organizational Affiliation
Northwell Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zucker Hillside Hospital
City
Queens
State/Province
New York
ZIP/Postal Code
11004
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albert Fenoy, MD
Phone
516-550-2100
Email
afenoy@northwell.edu
First Name & Middle Initial & Last Name & Degree
Miklos Argyelan, MD
Phone
7184708175
Email
margyelan@northwell.edu

12. IPD Sharing Statement

Citations:
PubMed Identifier
27288959
Citation
Fenoy AJ, Schulz P, Selvaraj S, Burrows C, Spiker D, Cao B, Zunta-Soares G, Gajwani P, Quevedo J, Soares J. Deep brain stimulation of the medial forebrain bundle: Distinctive responses in resistant depression. J Affect Disord. 2016 Oct;203:143-151. doi: 10.1016/j.jad.2016.05.064. Epub 2016 Jun 3.
Results Reference
background
PubMed Identifier
29867109
Citation
Fenoy AJ, Schulz PE, Selvaraj S, Burrows CL, Zunta-Soares G, Durkin K, Zanotti-Fregonara P, Quevedo J, Soares JC. A longitudinal study on deep brain stimulation of the medial forebrain bundle for treatment-resistant depression. Transl Psychiatry. 2018 Jun 4;8(1):111. doi: 10.1038/s41398-018-0160-4.
Results Reference
background
PubMed Identifier
35288633
Citation
Fenoy AJ, Schulz PE, Sanches M, Selvaraj S, Burrows CL, Asir B, Conner CR, Quevedo J, Soares JC. Deep brain stimulation of the "medial forebrain bundle": sustained efficacy of antidepressant effect over years. Mol Psychiatry. 2022 May;27(5):2546-2553. doi: 10.1038/s41380-022-01504-y. Epub 2022 Mar 14.
Results Reference
background

Learn more about this trial

DBS for Depression

We'll reach out to this number within 24 hrs